[
  {
    "section": "section:1",
    "title": "Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?"
  },
  {
    "section": "section:2",
    "title": "Introduction"
  },
  {
    "section": "section:2",
    "title": "Material and methods"
  },
  {
    "section": "section:2",
    "title": "Results"
  },
  {
    "section": "section:3",
    "title": "Patient and tumor characteristics"
  },
  {
    "section": "section:3",
    "title": "Univariate and multivariate analysis"
  },
  {
    "section": "section:3",
    "title": "Phase I clinical trial therapies"
  },
  {
    "section": "section:3",
    "title": "Phase I trial therapy-related toxicities"
  },
  {
    "section": "section:3",
    "title": "Antitumor activity"
  },
  {
    "section": "section:2",
    "title": "Discussion"
  },
  {
    "section": "section:2",
    "title": "Conflict of interest"
  },
  {
    "section": "section:2",
    "title": "Acknowledgements"
  },
  {
    "section": "section:2",
    "title": "References"
  }
]